ArticleJournal of the American Academy of Dermatology2018
Determination of the impact of melanoma surgical timing on survival using the National Cancer Database.
Article in Journal of the American Academy of Dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it.
- MelaNostrum: a consensus questionnaire of standardized epidemiologic and clinical variables for melanoma risk assessment by the melanostrum consortium.Journal of the European Academy of Dermatology and Venereology : JEADV · 2018Guideline
- Spatial and Single-Cell Multi-Omics Analyses of T-Cell Subsets and Interactions in Melanoma Lymph Node Metastasis.Experimental dermatology · 2026Review
- Article
- The CUBED Versus ABCDE Recognition Tools in the Detection of Malignant Melanomas Arising in the Foot: An Analysis of Four Recent Case Studies in a Single NHS Community Trust.Journal of foot and ankle research · 2026Article
- Teledermoscopy-Assisted Referral for Cutaneous Melanoma: Diagnostic Timeliness, Histopathologic Severity, and Stage at Excision in a Comparative Cohort.Journal of clinical medicine · 2026Article
- Disparities in time-to-treatment initiation and therapeutic modalities for malignant melanoma of the skin: a cross-sectional study, Brazil, 2013-2023.Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2026Article
- Facilitators and Barriers to the Timely Diagnosis and Treatment of Melanoma in Latino Persons.JAMA dermatology · 2025Article
- Bridging gaps throughout a patient's journey with melanoma: a systematic review.Melanoma management · 2025Review
- Teledermatology and Teledermoscopy for Melanoma Care Pathways: Timeliness, Diagnostic Performance, and Stage at Diagnosis: A Systematic Review.Diagnostics (Basel, Switzerland) · 2025Review
- Handoff Delays in Teledermatology Lengthen Timeline of Care for Veterans With Melanoma.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2025Article
- Dual-center retrospective cohort analysis of high-risk cutaneous squamous cell carcinoma tumors.Archives of dermatological research · 2025Article
- [Experimental Study on Biomimetic Curcumin-Mediated Sonodynamic Therapy of Melanoma].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024Article
- Wait times for scheduling appointments with hospital affiliated dermatologists in New York City.Archives of dermatological research · 2024Article
- When does a melanoma metastasize? Implications for management.Oncotarget · 2024Review
- Melanoma Detected Through Teledermatology Versus In-Person Visits.Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2024Article
- Exploring the relationship between total serum calcium and melanoma development: a cross-sectional study.Frontiers in nutrition · 2024Article
- Targeting superficial cancers with gold nanoparticles: a review of current research.Therapeutic delivery · 2024Review
- Changes in Health Care Costs, Survival, and Time Toxicity in the Era of Immunotherapy and Targeted Systemic Therapy for Melanoma.JAMA dermatology · 2023Article
- Large Language Models for Therapy Recommendations Across 3 Clinical Specialties: Comparative Study.Journal of medical Internet research · 2023Article
- Impact of the COVID-19 Pandemic on the Incidence and Thickness of Cutaneous Melanoma in Belgium.Biomedicines · 2023Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors.
Funding
Abstract
backgroundThe ideal timing for melanoma treatment, predominantly surgery, remains undetermined. Patient concern for receiving immediate treatment often exceeds surgeon or hospital availability, requiring establishment of a safe window for melanoma surgery.
objectiveTo assess the impact of time to definitive melanoma surgery on overall survival.
methodsPatients with stage I to III cutaneous melanoma and with available time to definitive surgery and overall survival were identified by using the National Cancer Database (N = 153,218). The t test and chi-square test were used to compare variables. Cox regression was used for multivariate analysis.
resultsIn a multivariate analysis of patients in all stages who were treated between 90 and 119 days after biopsy (hazard ratio [HR], 1.09; 95% confidence interval [CI], 1.01-1.18) and more than 119 days (HR, 1.12; 95% CI, 1.02-1.22) had a higher risk for mortality compared with those treated within 30 days of biopsy. In a subgroup analysis of stage I, higher mortality risk was found in patients treated within 30 to 59 days (HR, 1.05; 95% CI, 1.01-1.1), 60 to 89 days (HR, 1.16; 95% CI, 1.07-1.25), 90 to 119 days (HR, 1.29; 95% CI, 1.12-1.48), and more than 119 days after biopsy (HR, 1.41; 95% CI, 1.21-1.65). Surgical timing did not affect survival in stages II and III. LIMITATIONS: Melanoma-specific survival was not available.
conclusionExpeditious treatment of stage I melanoma is associated with improved outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.